Table 3.
Prevalence of resistance % | ||||||
---|---|---|---|---|---|---|
AMP | SXT | TET | CHL | NAL | CIP | |
Age | ||||||
6-23 months | 73* | 73* | 76 | 46* | 30 | 0.3 |
24-60 months § | 59 | 64 | 74 | 37 | 24 | 0.2 |
Household economic status | ||||||
Below average | 67 | 68 | 78 | 40 | 24 | 0.3 |
Average and above § | 64 | 68 | 72 | 41 | 29 | 0.2 |
Geographical area | ||||||
Lowland | 60 | 66 | 68* | 41 | 30 | 0.0 |
Highland | 73 | 67 | 78 | 43 | 27 | 0.4 |
Mountains § | 62 | 72 | 78 | 39 | 23 | 0.4 |
Any reported antibiotic use in prior 21 days | ||||||
No | 56 | 63 | 73 | 37 | 23 | 0.6 |
Yes | 72 | 72 | 76 | 44 | 30 | 0.0 |
*Result was statistically significant using binomial logistic regression
§Reference group used in binomial logistic regression
Abbreviations used: TET = tetracycline; SXT = co-trimoxazole; AMP = ampicillin; CHL = chloramphenicol; NAL = nalidixic acid; CIP = ciprofloxacin
The results presented are based on data interpreted using CLSI clinical breakpoints